Thoratec Seeks 'Cultural Revolution' As Rival HeartWare Makes Strides
This article was originally published in The Gray Sheet
Executive Summary
The long-time leader of the ventricular assist device market Thoratec is implementing plans to get back on track for future growth, while rival HeartWare recently reported rapid global expansion and aggressive R&D investments.
You may also be interested in...
VADs Set To Enter Big Leagues With St. Jude's Plan To Acquire Thoratec
St. Jude Medical says it will pay $3.4 billion to own ventricular-assist device leader Thoratec, pointing to significant synergies in the heart failure and interventional cardiology markets. The deal would thrust VADs into a diversified cardiology firm for the first time, and it includes a "go-shop" period that leaves an opening for other big device firms to enter competing bids.
VADs Set To Enter Big Leagues With St. Jude's Plan To Acquire Thoratec
St. Jude Medical says it will pay $3.4 billion to own ventricular-assist device leader Thoratec, pointing to significant synergies in the heart failure and interventional cardiology markets. The deal would thrust VADs into a diversified cardiology firm for the first time, and it includes a "go-shop" period that leaves an opening for other big device firms to enter competing bids.
Thoratec On Track For Late 2015 HeartMate III Launch
Enrollment has been completed in the firm's 50-patient trial to support a European CE mark of its next generation HeartMate III.